CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to EXEL

Cabozantinib

Phase 3
Exelixis, Inc. (EXEL)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jan '27
EXELPDUFA
Phase 3Approved

FDA PDUFA Date cabozantinib (priority)

Cabozantinib
Jan 2027~
SEC
Competitive Landscape

1 competitor in Solid Tumors

View Full Landscape
Drug Information

Target Indication

Solid Tumors

Clinical Trial

NCT00940225

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.